Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CETP | P11597 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16063220 | 0.83 | NPC1 (0.65) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL17831066 | 0.83 | LMNA (0.64) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL9923070 | 0.79 | HPGD (0.65) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL14184555 | 0.79 | POLB (0.67) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL20941777 | 0.79 | NOTUM (0.70) | POLBALDH1A1MAPTMAPK1CETP | |
| SCHEMBL12883303 | 0.77 | MEN1 (0.56) | POLBMEN1KMT2AKDM4EMAPT | |
| SCHEMBL19392493 | 0.77 | MAPT (0.57) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3416858 | 0.77 | HPGD (0.62) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2625088 | 0.77 | POLB (0.76) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL11211388 | 0.76 | SMN1; SMN2 (0.64) | POLBMEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138356-B2 | Chemical inhibitors of inhibitors of differentiation | Angiogeney, Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | BRAF, MAPK1, RAF1 | POLB 3542/4885ALDH1A1 1860/4885MEN1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.